
FDA approves first treatment for rare type of glioma
The US Food and Drug Administration (FDA) has granted accelerated approval for Modeyso (dordaviprone) for the treatment of patients one year of age and older with diffuse midline glioma harbouring an H3 K27M mutation with progressive disease following prior therapy. The FDA has stated that continued approval for this indication… Read More




